BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2993411)

  • 1. Surface marker characterization of EBV target cells in normal blood and tonsil B lymphocyte populations.
    Aman P; Gordon J; Lewin N; Nordström M; Ehlin-Henriksson B; Klein G; Carstensson A
    J Immunol; 1985 Oct; 135(4):2362-7. PubMed ID: 2993411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of EBV-transformable human B lymphocyte populations.
    Chan MA; Stein LD; Dosch HM; Sigal NH
    J Immunol; 1986 Jan; 136(1):106-12. PubMed ID: 2999241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis of Epstein-Barr virus transformation of human lymphocytes: susceptibility of B lymphocyte subpopulations and differentiation stage of the transformed cells].
    Koizumi S
    Hokkaido Igaku Zasshi; 1985 Sep; 60(5):724-34. PubMed ID: 3000906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BLAST-2 [EBVCS], an early cell surface marker of human B cell activation, is superinduced by Epstein Barr virus.
    Thorley-Lawson DA; Nadler LM; Bhan AK; Schooley RT
    J Immunol; 1985 May; 134(5):3007-12. PubMed ID: 2984280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of an activated b lymphocyte-associated surface moiety defined by the B2 monoclonal antibody by ebv conversion of an EBV-negative lymphoma line (Ramos): differential effect of transforming (B95-8) and nontransforming (P3HR-1) EBV substrains.
    Klein G; Ehlin-Henriksson B; Schlossman SF
    J Immunol; 1983 Apr; 130(4):1985-9. PubMed ID: 6300235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotype, frequency, and EBV responsiveness of human marrow B and pre-B cells.
    Hibi T; Chan MA; Petsche D; Dosch HM
    J Immunol; 1986 May; 136(9):3211-8. PubMed ID: 3007613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in the phenotype and immunoglobulin secretion of human B cells following co-culture with cells of an EBV+ lymphoblastoid line or fusion with mouse plasmacytoma cells. Studies in short-term and long-term culture.
    Ling NR; Lowe JA
    Clin Exp Immunol; 1989 Feb; 75(2):311-6. PubMed ID: 2539279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus preferentially induces proliferation of primed B cells.
    Crain MJ; Sanders SK; Butler JL; Cooper MD
    J Immunol; 1989 Sep; 143(5):1543-8. PubMed ID: 2547870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas.
    Yokochi T; Holly RD; Clark EA
    J Immunol; 1982 Feb; 128(2):823-7. PubMed ID: 6274961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD44 isoforms containing exons V6 and V7 are differentially expressed on mitogenically stimulated normal and Epstein-Barr virus-transformed human B cells.
    Kryworuckho M; Diaz-Mitoma F; Kumar A
    Immunology; 1995 Sep; 86(1):41-8. PubMed ID: 7590880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new antigen identified by the monoclonal antibody UCHB 1 delivers a costimulatory signal to a subset of human B cells.
    Armitage RJ; Rowe DJ; Beverly PC
    Eur J Immunol; 1988 Jan; 18(1):67-76. PubMed ID: 3257923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a subset of normal B cells with a Burkitt's lymphoma (BL)-like phenotype.
    Gregory CD; Tursz T; Edwards CF; Tetaud C; Talbot M; Caillou B; Rickinson AB; Lipinski M
    J Immunol; 1987 Jul; 139(1):313-8. PubMed ID: 2953817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation and functional analysis of human B cell populations. I. Characterization of the B1+B2+ and B1+B2- subsets.
    Anderson KC; Boyd AW; Fisher DC; Slaughenhoupt B; Groopman JE; O'Hara CJ; Daley JF; Schlossman SF; Nadler LM
    J Immunol; 1985 Feb; 134(2):820-7. PubMed ID: 3917476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural cytotoxicity against mouse hepatitis virus-infected cells. II. A cytotoxic effector cell with a B lymphocyte phenotype.
    Welsh RM; Haspel MV; Parker DC; Holmes KV
    J Immunol; 1986 Feb; 136(4):1454-60. PubMed ID: 3003199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of isotype commitment in human B cells: limiting dilution analysis of Epstein Barr virus-infected cells.
    Stein LD; Ledgley CJ; Sigal NH
    J Immunol; 1983 Apr; 130(4):1640-5. PubMed ID: 6300231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between immunoglobulin production and immortalization by Epstein Barr virus.
    Tosato G; Blaese RM; Yarchoan R
    J Immunol; 1985 Aug; 135(2):959-64. PubMed ID: 2989369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and characterization of a human B cell line that responds to B cell growth factor but not interleukin 2.
    Tseng CT; Springgate CF; Piela TH; Choi YS
    J Immunol; 1987 Apr; 138(8):2554-60. PubMed ID: 3031160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human B cell development. I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue.
    Campana D; Janossy G; Bofill M; Trejdosiewicz LK; Ma D; Hoffbrand AV; Mason DY; Lebacq AM; Forster HK
    J Immunol; 1985 Mar; 134(3):1524-30. PubMed ID: 3918103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Requirement of Ia-positive accessory cells in the MLR response against class II antigen on human B cell tumor line.
    Yamamoto M; Yano A
    J Immunol; 1985 Dec; 135(6):3887-96. PubMed ID: 2999233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus susceptibility of normal human B lymphocyte populations.
    Aman P; Ehlin-Henriksson B; Klein G
    J Exp Med; 1984 Jan; 159(1):208-20. PubMed ID: 6319530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.